Trial of Eltrombopag During Consolidation Therapy in Adults With AML in Complete Remission
Status:
Terminated
Trial end date:
2016-03-01
Target enrollment:
Participant gender:
Summary
Patients with Acute Myeloid Leukemia (AML) in complete remission will receive eltrombopag
while undergoing consolidation chemotherapy with high-dose cytarabine. Eltrombopag may help
increase the number of platelets during chemotherapy and may help prevent the risk of
bleeding.
Phase I will study the side effects, best dose and platelet effects of eltrombopag when given
with consolidation chemotherapy. After the maximum safe and tolerated dose and schedule is
found in Phase I, the study will proceed to Phase II. Phase II will confirm the dose and
schedule of eltrombopag identified in Phase I that can increase platelet counts in patients
receiving consolidation therapy.